On bupropion (Wellbutrin) 300 mg daily, anxiety has improved but the patient reports a sour mood; what medication should be added to address the mood?

Add an SSRI to Address the Sour Mood

For a patient on bupropion 300 mg daily with improved anxiety but persistent "sour mood," add an SSRI such as sertraline (starting 25-50 mg daily) or escitalopram (starting 10 mg daily) to target the depressive symptoms. This combination strategy is well-supported and addresses the incomplete mood response while maintaining the anxiety benefits already achieved.

Rationale for SSRI Addition

Bupropion at 300 mg is FDA-approved for major depression and has demonstrated efficacy 1, but it lacks serotonergic activity—a mechanism often crucial for addressing core depressive mood symptoms. The patient's "sour mood" despite anxiety improvement suggests inadequate serotonergic modulation. Combining bupropion with an SSRI is a validated augmentation strategy that targets multiple neurotransmitter systems simultaneously 2.

Evidence Supporting Combination Therapy

• Moderate-certainty evidence shows no significant difference in efficacy between augmenting with bupropion versus switching antidepressants in patients with inadequate response 3, 4
• Open-label studies demonstrate that bupropion combined with SSRIs is effective for treatment-resistant depression and is generally well-tolerated 2
• The combination addresses both noradrenergic/dopaminergic (bupropion) and serotonergic (SSRI) pathways 2, 5

Specific SSRI Selection

Sertraline (25-50 mg daily, titrate to 200 mg) or escitalopram (10 mg daily, titrate to 40 mg) are preferred choices 6, 7:

• Sertraline: Well-tolerated with fewer drug-drug interactions compared to other SSRIs; less effect on metabolism of other medications 6
• Escitalopram: Comparable efficacy to bupropion in head-to-head trials with generally similar tolerability 8

Avoid paroxetine due to higher anticholinergic effects and increased sexual dysfunction risk 7. Fluoxetine's very long half-life may complicate dose adjustments 6.

Dosing Strategy

1. Continue bupropion 300 mg daily (already providing anxiety benefit)
2. Start SSRI at low dose: Sertraline 25-50 mg or escitalopram 10 mg daily
3. Titrate weekly based on response and tolerability
4. Assess response at 4-8 weeks on therapeutic doses 6
5. Target remission, not just response—54% of patients don't achieve remission with monotherapy 7

Critical Safety Considerations

Monitor for Activation/Agitation

Bupropion is described as "activating" and should not be used in agitated patients 6. While the patient's anxiety has improved, monitor for:

• Increased restlessness or agitation when adding SSRI
• Insomnia (give second bupropion dose before 3 PM if using divided dosing) 6
• Activation of mania/hypomania (screen for bipolar risk factors) 9

Seizure Risk

Bupropion 300 mg carries approximately 0.1% seizure risk 9. Do not exceed 450 mg total daily dose and avoid in patients with:

• History of seizures or eating disorders
• Conditions lowering seizure threshold
• Concurrent medications that lower seizure threshold

Blood Pressure Monitoring

Check blood pressure before and during treatment 9. Bupropion can cause hypertension, particularly when combined with other agents affecting noradrenergic activity.

Drug Interactions

SSRIs inhibit various cytochrome P450 enzymes 6. Sertraline has the least interaction potential among SSRIs. Avoid MAOIs (14-day washout required) 9.

Alternative Consideration: Mirtazapine

If the patient has concurrent insomnia or poor appetite, mirtazapine 7.5-30 mg at bedtime is an alternative augmentation strategy 6:

• Potent and well-tolerated
• Promotes sleep, appetite, and weight gain
• Different mechanism (alpha-2 antagonist, 5-HT2/5-HT3 antagonist)
• May be sedating (beneficial if insomnia present)

What NOT to Do

Do not simply increase bupropion dose beyond 300 mg without adding another agent. While bupropion can be increased to 450 mg daily 9, this patient's specific complaint of "sour mood" with improved anxiety suggests a serotonergic deficit that higher bupropion doses won't address. The activating properties of bupropion may worsen irritability without targeting core depressive symptoms 6.

Do not switch away from bupropion since anxiety has already improved—this represents a partial response worth building upon 4.

Expected Timeline

• Anxiety: Already improved (continue monitoring)
• Mood improvement: Expect initial changes within 2-4 weeks, full effect by 6-8 weeks 6
• Reassess at 12 weeks: If <5% improvement in depressive symptoms, consider alternative strategies 3

Common Pitfalls to Avoid

1. Premature discontinuation: Full therapeutic trial requires 4-8 weeks at therapeutic doses 6
2. Inadequate dosing: Many patients require higher SSRI doses for full response
3. Ignoring sexual dysfunction: Bupropion has lower sexual dysfunction rates than SSRIs 7; if this emerges with SSRI addition, it may offset bupropion's advantage
4. Missing bipolar disorder: Screen for personal/family history before initiating—antidepressants can precipitate mania 9